Advertisement

Corticosteroid switch after progression on abiraterone acetate plus prednisone

  • Giandomenico RovielloEmail author
  • Navid Sobhani
  • Silvia Paola Corona
  • Alberto D’Angelo
Review Article
  • 35 Downloads

Abstract

Introduction

Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.

Materials and Methods

The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option.

Results

A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223.

Conclusion

Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.

Keywords

Dexamethasone Prednisone Abiraterone Switch 

Notes

Funding

No Funding.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA Cancer J Clin. 68:7–30CrossRefGoogle Scholar
  2. 2.
    Crawford ED, Petrylak D, Sartor O (2017) Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 35S:S1–S13CrossRefGoogle Scholar
  3. 3.
    de Bono JS et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005CrossRefGoogle Scholar
  4. 4.
    Ryan CJ et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148CrossRefGoogle Scholar
  5. 5.
    Attard G, Reid AH, Olmos D et al (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937–4940CrossRefGoogle Scholar
  6. 6.
    Dizdar O (2015) Is dexamethasone a better partner for abiraterone than prednisolone? Oncologist 20(5):e13CrossRefGoogle Scholar
  7. 7.
    Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. (Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365)CrossRefGoogle Scholar
  8. 8.
    Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160.CrossRefGoogle Scholar
  9. 9.
    Roviello G, Sigala S, Danesi R et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 101:12–20CrossRefGoogle Scholar
  10. 10.
    Eichholz A, Ferraldeschi R, Attard G et al (2012) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 360:68–75CrossRefGoogle Scholar
  11. 11.
    Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ et al (2001) Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7:11–15Google Scholar
  12. 12.
    Crona DJ, Whang YE (2017) Androgen receptor‑dependent and independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel) 9: pii: E67Google Scholar
  13. 13.
    Arora VK, Schenkein E, Murali R et al (2013) Glucocorticoid receptor confers resistance to antiandrogens bybypassing androgen receptor blockade. Cell 155:1309–1322CrossRefGoogle Scholar
  14. 14.
    Lan NC, Graham B, Bartter FC et al (1982) Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Metab 54:332–342CrossRefGoogle Scholar
  15. 15.
    Dovio A, Sartori ML, De Francia S et al (2009) Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. J Steroid Biochem Mol Biol 116:29–36CrossRefGoogle Scholar
  16. 16.
    Leach DA, Powell SM, Bevan CL (2016) Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocr Relat Cancer 23:T85–T108CrossRefGoogle Scholar
  17. 17.
    Taplin ME, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398CrossRefGoogle Scholar
  18. 18.
    Zhao XY, Malloy PJ, Krishnan AV et al (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703–706CrossRefGoogle Scholar
  19. 19.
    Richards J, Lim AC, Hay CW et al (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild‑type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72: 2176‑2182Google Scholar
  20. 20.
    Nishimura K, Nonomura N, Satoh E et al (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93:1739–1746CrossRefGoogle Scholar
  21. 21.
    Lam JS, Leppert JT, Vemulapalli SN et al (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175:27–34CrossRefGoogle Scholar
  22. 22.
    Yano A, Fujii Y, Iwai A et al (2006) Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12:3003–3009CrossRefGoogle Scholar
  23. 23.
    Akakura K, Suzuki H, Ueda T et al (2003) Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 56:106–109CrossRefGoogle Scholar
  24. 24.
    Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076–7085CrossRefGoogle Scholar
  25. 25.
    Komiya A, Shimbo M, Suzuki H et al (2010) Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett 1:73–79CrossRefGoogle Scholar
  26. 26.
    Diederich S, Scholz T, Eigendorff E et al (2004) Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and gluco-corticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res 36:423–429CrossRefGoogle Scholar
  27. 27.
    Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570–2576CrossRefGoogle Scholar
  28. 28.
    Lorente D, Omlin A, Ferraldeschi R et al (2014) Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 111:2248–2253CrossRefGoogle Scholar
  29. 29.
    Fenioux C, Louvet C, Charton E et al (2018) Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU IntGoogle Scholar
  30. 30.
    Romero-Laorden N, Lozano R, Jayaram A et al (2018) Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J CancerGoogle Scholar
  31. 31.
    Roviello G, Petrioli R, Bonetta A et al (2018) Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Invest New Drugs 2018Google Scholar
  32. 32.
    Venkitaraman R, Lorente D, Murthy V et al (2015) A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67:673–679CrossRefGoogle Scholar
  33. 33.
    Sobhani N, Generali D, D’Angelo A et al (2018) Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest. New Drugs.  https://doi.org/10.1007/s10637-018-0653-2 CrossRefPubMedGoogle Scholar
  34. 34.
    Gillessen S et al (2015) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589–1604CrossRefGoogle Scholar
  35. 35.
    James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-linelong-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet 387:1163–1177CrossRefGoogle Scholar
  36. 36.
    Francini E, Petrioli R, Roviello G (2014) No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 14(10):1135–1140CrossRefGoogle Scholar
  37. 37.
    Petrioli R, Francini E, Roviello G (2015) Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 6(5):99–103CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Giandomenico Roviello
    • 1
    Email author
  • Navid Sobhani
    • 2
    • 3
  • Silvia Paola Corona
    • 2
  • Alberto D’Angelo
    • 4
  1. 1.Department of Health SciencesUniversity of FlorenceFlorenceItaly
  2. 2.Department of Medical, Surgical and Health SciencesUniversity of Trieste, Cattinara HospitalTriesteItaly
  3. 3.Breast Cancer UnitASST CremonaCremonaItaly
  4. 4.Department of Biology and BiochemistryUniversity of BathBathUK

Personalised recommendations